Regulation of hepatic steroid receptors and enzymes by the 3β-hydroxysteroid dehydrogenase inhibitor trilostane

Journal of Steroid Biochemistry and Molecular Biology

Volumn 101, Issue 2-3, 2006, Pages 97-105

  Malouitre, S D M ^a   Barker, S ^a   Puddefoot, J R ^a   Jalili, J ^a   Glover, H R ^a   Vinson, G P ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

11 Hydroxysteroid dehydrogenase; 3 Hydroxysteroid dehydrogenase 5 4 isomerase; Corticosteroids; Cushing's syndrome; GR; Hepatic gene regulation; Hypercortisolism; Trilostane

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; 11BETA HYDROXYSTEROID DEHYDROGENASE TYPE 2; 3(OR 17)BETA HYDROXYSTEROID DEHYDROGENASE; 3BETA HYDROXYSTEROID DEHYDROGENASE INHIBITOR; ALDOSTERONE; CORTICOSTEROID; CORTICOSTERONE; DNA; ENZYME INHIBITOR; GLUCOCORTICOID RECEPTOR; MESSENGER RNA; MINERALOCORTICOID RECEPTOR; TRILOSTANE; UNCLASSIFIED DRUG;

ALDOSTERONE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORTICOSTEROID BLOOD LEVEL; CORTICOSTERONE BLOOD LEVEL; CUSHING SYNDROME; DNA RESPONSIVE ELEMENT; DRUG ACTIVITY; GENE CONTROL; GENETIC TRANSCRIPTION; HYPERCORTISOLISM; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN ANALYSIS; RAT; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA TRANSLATION; THERAPY EFFECT; TISSUE SECTION; TREATMENT OUTCOME;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 2; 17-HYDROXYSTEROID DEHYDROGENASES; ADRENAL CORTEX HORMONES; ANIMALS; CELL LINE; DIHYDROTESTOSTERONE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; LIVER; MALE; RATS; RATS, WISTAR; RECEPTORS, GLUCOCORTICOID; RECEPTORS, STEROID; RNA, MESSENGER; TRANSCRIPTION, GENETIC; TRANSFECTION;

RATTUS NORVEGICUS;

EID: 33748134644     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2006.06.008     Document Type: Article

References (54)

1. Engelhardt D., and Weber M.M. Therapy of Cushing's syndrome with steroid biosynthesis inhibitors. J. Steroid Biochem. Mol. Biol. 49 (1994) 261-267
2. Williams C.J., Barley V., Blackledge G., Hutcheon A., Kaye S., Smith D., Keen C., Webster D.J., Rowland C., and Tyrrell C. Multicenter study of trilostane: a new hormonal agent in advanced postmenopausal breast cancer. Cancer Treat Rep. 71 (1987) 1197-1201
3. Leonard R.C.F., Bundred N., Canney P., Rea D., Rowland C., Spittle M., Stewart A., Verrill M., Vinson G., and Wood C. Meta analysis of trilostane (Modrenal) in advanced post-menopausal breast cancer evaluated by priorexposure to anti-oestrogen treatments. Eur. J. Cancer 1 (2003) 47
4. Coombes R.C., Powles T.J., Muindi J., Hunt J., Ward M., Perez D., and Neville A.M. Trilostane therapy for advanced breast cancer. Cancer Treat Rep. 69 (1985) 351-354
5. Dewis P., Anderson D.C., Bu'lock D.E., Earnshaw R., and Kelly W.F. Experience with trilostane in the treatment of Cushing's syndrome. Clin. Endocrinol. (Oxford) 18 (1983) 533-540
6. Semple C.G., Beastall G.H., Gray C.E., and Thomson J.A. Trilostane in the management of Cushing's syndrome. Acta Endocrinol. (Copenhagn) 102 (1983) 107-110
7. Winterberg B., Vetter W., Groth H., Greminger P., and Vetter H. Primary aldosteronism: treatment with trilostane. Cardiology 72 Suppl. 1 (1985) 117-121
8. Potts G.O., Creange J.E., Hardomg H.R., and Schane H.P. Trilostane, an orally active inhibitor of steroid biosynthesis. Steroids 32 (1978) 257-267
9. Komanicky P., Spark R.F., and Melby J.C. Treatment of Cushing's syndrome with trilostane (WIN 24,540), an inhibitor of adrenal steroid biosynthesis. J. Clin. Endocrinol. Metab. 47 (1978) 1042-1051
10. Semple C.G., Weir S.W., Thomson J.A., and Beastall G.H. Trilostane and the normal hypothalamic-pituitary-testicular axis. Clin. Endocrinol. (Oxford) 17 (1982) 99-102
11. Semple C.G., Thomson J.A., Stark A.N., McDonald M., and Beastall G.H. Trilostane and the normal hypothalamic-pituitary-adrenocortical axis. Clin. Endocrinol. (Oxford) 17 (1982) 569-575
12. Vierhapper H., Nowotny P., and Waldhausl W. Effect of trilostan on steroid excretion in man: compensated inhibition of 3β-hydroxysteroid dehydrogenase. J. Steroid Biochem. 24 (1986) 577-580
13. Sillence M.N., and Rodway R.G. Age- and sex-dependent stimulation of growth rate in rats by the adrenal inhibitor trilostane. J. Endocrinol. 113 (1987) 479-484
14. Neiger R., Ramsey I., O'Connor J., Hurley K.J., and Mooney C.T. Trilostane treatment of 78 dogs with pituitary-dependent hyperadrenocorticism. Vet. Rec. 150 (2002) 799-804
15. Puddefoot J.R., Barker S., Glover H.R., Malouitre S.D., and Vinson G.P. Non-competitive steroid inhibition of oestrogen receptor functions. Int. J. Cancer 101 (2002) 17-22
16. Livingstone D.E., Jones G.C., Smith K., Jamieson P.M., Andrew R., Kenyon C.J., and Walker B.R. Understanding the role of glucocorticoids in obesity: tissue-specific alterations of corticosterone metabolism in obese Zucker rats. Endocrinology 141 (2000) 560-563
17. 5,4-isomerase gene family. Endocr. Rev. 26 (2005) 525-582
18. Tomlinson J.W., Moore J.S., Clark P.M., Holder G., Shakespeare L., and Stewart P.M. Weight loss increases 11β-hydroxysteroid dehydrogenase type 1 expression in human adipose tissue. J. Clin. Endocrinol. Metab. 89 (2004) 2711-2716
19. Xu R.B., Liu Z.M., and Zhao Y. A study on the circadian rhythm of glucocorticoid receptor. Neuroendocrinology 53 Suppl. 1 (1991) 31-36
20. Maser E., and Bannenberg G. The purification of 11β-hydroxysteroid dehydrogenase from mouse liver microsomes. J. Steroid Biochem. Mol. Biol. 48 (1994) 257-263
21. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 (1970) 680-685
22. Naville D., Keeney D.S., Jenkin G., Murry B.A., Head J.R., and Mason J.I. Regulation of expression of male-specific rat liver microsomal 3β-hydroxysteroid dehydrogenase. Mol. Endocrinol. 5 (1991) 1090-1100
23. 5,4-isomerase expression in rat and characterization of the testis isoform. Mol. Cell. Endocrinol. 80 (1991) 21-31
24. 5,4-isomerase by site-directed mutagenesis and expression in HeLa cells. J. Biol. Chem. 266 (1991) 14842-14845
25. 5,4-isomerase (3β-HSD) family. The exclusive 3β-HSD gene expression in the skin. J. Biol. Chem. 268 (1993) 19659-19668
26. 5,4-isomerase cDNAs and differential tissue-specific expression of the corresponding mRNAs in steroidogenic and peripheral tissues. J. Biol. Chem. 266 (1991) 583-593
27. Boag A.K., Neiger R., and Church D.B. Trilostane treatment of bilateral adrenal enlargement and excessive sex steroid hormone production in a cat. J. Small Anim. Pract. 45 (2004) 263-266
28. Eastwood J.M., Elwood C.M., and Hurley K.J. Trilostane treatment of a dog with functional adrenocortical neoplasia. J. Small Anim. Pract. 44 (2003) 126-131
29. McGowan C.M., and Neiger R. Efficacy of trilostane for the treatment of equine Cushing's syndrome. Equine Vet. J. 35 (2003) 414-418
30. Ruckstuhl N.S., Nett C.S., and Reusch C.E. Results of clinical examinations, laboratory tests, and ultrasonography in dogs with pituitary-dependent hyperadrenocorticism treated with trilostane. Am. J. Vet. Res. 63 (2002) 506-512
31. Skelly B.J., Petrus D., and Nicholls P.K. Use of trilostane for the treatment of pituitary-dependent hyperadrenocorticism in a cat. J. Small Anim. Pract. 44 (2003) 269-272
32. Bamberger C.M., Schulte H.M., and Chrousos G.P. Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids. Endocr. Rev. 17 (1996) 245-261
33. Draper N., and Stewart P.M. 11β-Hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action. J. Endocrinol. 186 (2005) 251-271
34. Seckl J.R. 11β-hydroxysteroid dehydrogenases: changing glucocorticoid action. Curr. Opin. Pharmacol. 4 (2004) 597-602
35. Zhao H.F., Rheaume E., Trudel C., Couet J., Labrie F., and Simard J. Structure and sexual dimorphic expression of a liver-specific rat 3β-hydroxysteroid dehydrogenase/isomerase. Endocrinology 127 (1990) 3237-3239
36. Naville D., Keeney D.S., Jenkin G., Murry B.A., Head J.R., and Mason J.I. Regulation of expression of male-specific rat liver microsomal 3β-hydroxysteroid dehydrogenase. Mol. Endocrinol. 5 (1991) 1090-1100
37. Simpson E.R., Misso M., Hewitt R.A., Boon W.C., Jones M.E., Kovacic A., Zhou J., and Clyne C.D. Estrogen-the good, the bad, and the unexpected. Endocr. Rev. 26 (2005) 322-330
38. Dong Y., Poellinger L., Gustafsson J.A., and Okret S. Regulation of glucocorticoid receptor expression: evidence for transcriptional and posttranslational mechanisms. Mol. Endocrinol. 2 (1988) 1256-1264
39. Okret S., Poellinger L., Dong Y., and Gustafsson J.A. Down-regulation of glucocorticoid receptor mRNA by glucocorticoid hormones and recognition by the receptor of a specific binding sequence within a receptor cDNA clone. Proc. Natl. Acad. Sci. U.S.A. 83 (1986) 5899-5903
40. Masuzaki H., Paterson J., Shinyama H., Morton N.M., Mullins J.J., Seckl J.R., and Flier J.S. A transgenic model of visceral obesity and the metabolic syndrome. Science 294 (2001) 2166-2170
41. Masuzaki H., Yamamoto H., Kenyon C.J., Elmquist J.K., Morton N.M., Paterson J.M., Shinyama H., Sharp M.G.F., Fleming S., Mullins J.J., Seckl J.R., and Flier J.S. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J. Clin. Invest. 112 (2003) 83-90
42. Bertram C., Trowern A.R., Copin N., Jackson A.A., and Whorwood C.B. The maternal diet during pregnancy programs altered expression of the glucocorticoid receptor and type 2 11beta-hydroxysteroid dehydrogenase: potential molecular mechanisms underlying the programming of hypertension in utero. Endocrinology 142 (2001) 2841-2853
43. Sun K., Yang K., and Challis J.R. Regulation of 11β-hydroxysteroid dehydrogenase type 2 by progesterone, estrogen, and the cyclic adenosine 5′-monophosphate pathway in cultured human placental and chorionic trophoblasts. Biol. Reprod. 58 (1998) 1379-1384
44. Touitou Y., Auzeby A., Bogdan A., Luton J.P., and Galan P. 11β-Hydroxy-11-ketosteroids equilibrium, a source of misinterpretation in steroid synthesis: evidence through the effects of trilostane on 11β-hydroxysteroid dehydrogenase in sheep and human adrenals in vitro. J. Steroid Biochem. 20 (1984) 763-768
45. Thompson A., Han V.K., and Yang K. Spatial and temporal patterns of expression of 11beta-hydroxysteroid dehydrogenase types 1 and 2 messenger RNA and glucocorticoid receptor protein in the murine placenta and uterus during late pregnancy. Biol. Reprod. 67 (2002) 1708-1718
46. Thompson A., Han V.K., and Yang K. Differential expression of 11β-hydroxysteroid dehydrogenase types 1 and 2 mRNA and glucocorticoid receptor protein during mouse embryonic development. J. Steroid Biochem. Mol. Biol. 88 (2004) 367-375
47. Diaz R., Brown R.W., and Seckl J.R. Distinct ontogeny of glucocorticoid and mineralocorticoid receptor and 11β-hydroxysteroid dehydrogenase types I and II mRNAs in the fetal rat brain suggest a complex control of glucocorticoid actions. J. Neurosci. 18 (1998) 2570-2580
48. Brown R.W., Diaz R., Robson A.C., Kotelevtsev Y.V., Mullins J.J., Kaufman M.H., and Seckl J.R. The ontogeny of 11β-hydroxysteroid dehydrogenase type 2 and mineralocorticoid receptor gene expression reveal intricate control of glucocorticoid action in development. Endocrinology 137 (1996) 794-797
49. Suzuki S., Koyama K., Darnel A., Ishibashi H., Kobayashi S., Kubo H., Suzuki T., Sasano H., and Krozowski Z.S. Dexamethasone upregulates 11β-hydroxysteroid dehydrogenase type 2 in BEAS-2B cells. Am. J. Respir. Crit. Care Med. 167 (2003) 1244-1249
50. van Beek J.P., Guan H., Julan L., and Yang K. Glucocorticoids stimulate the expression of 11β-hydroxysteroid dehydrogenase type 2 in cultured human placental trophoblast cells. J. Clin. Endocrinol. Metab. 89 (2004) 5614-5621
51. Darnel A.D., Archer T.K., and Yang K. Regulation of 11β-hydroxysteroid dehydrogenase type 2 by steroid hormones and epidermal growth factor in the Ishikawa human endometrial cell line. J. Steroid Biochem. Mol. Biol. 70 (1999) 203-210
52. Arcuri F., Sestini S., Ricci C., Runci Y., Carducci A., Paulesu L., and Cintorino M. Progestin regulation of 11β-hydroxysteroid dehydrogenase expression in T-47D human breast cancer cells. J. Steroid Biochem. Mol. Biol. 72 (2000) 239-247
53. Paterson J.M., Morton N.M., Fievet C., Kenyon C.J., Holmes M.C., Staels B., Seckl J.R., and Mullins J.J. Metabolic syndrome without obesity: hepatic overexpression of 11β-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 7088-7093
54. Kinyamu H.K., and Archer T.K. Estrogen receptor-dependent proteasomal degradation of the glucocorticoid receptor is coupled to an increase in mdm2 protein expression. Mol. Cell. Biol. 23 (2003) 5867-5881